KalVista Pharmaceuticals (KALV)
Market Price (5/17/2026): $26.75 | Market Cap: $1.5 BilSector: Health Care | Industry: Biotechnology
KalVista Pharmaceuticals (KALV)
Market Price (5/17/2026): $26.75Market Cap: $1.5 BilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -55% Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. | Trading close to highsDist 52W High is -0.3%, Dist 3Y High is -0.3% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -319% Stock price has recently run up significantly12M Rtn12 month market price return is 124% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17% Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 28% Key risksKALV key risks include [1] its heavy reliance on the commercial success of its single approved drug, Show more. |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -55% |
| Megatrend and thematic driversMegatrends include Precision Medicine. Themes include Targeted Therapies, and Biopharmaceutical R&D. |
| Trading close to highsDist 52W High is -0.3%, Dist 3Y High is -0.3% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -179 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -319% |
| Stock price has recently run up significantly12M Rtn12 month market price return is 124% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 25% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -17% |
| Significant short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 28% |
| Key risksKALV key risks include [1] its heavy reliance on the commercial success of its single approved drug, Show more. |
Qualitative Assessment
AI Analysis | Feedback
KalVista Pharmaceuticals (KALV) stock has gained about 70% since 1/31/2026 because of the following key factors:
1. Acquisition by Chiesi Group. The most significant factor driving the stock increase was the announcement on April 29, 2026, that Chiesi Group would acquire KalVista Pharmaceuticals for $27.00 per share in cash. This represented an equity consideration of approximately $1.9 billion and a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026, causing the stock to surge by approximately 38-39%.
2. Positive Interim Phase 3 Results for Pediatric HAE Treatment. KalVista announced positive interim data on March 30, 2026, from its KONFIDENT-KID Phase 3 trial evaluating EKTERLY (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children aged 2-11 years. This development highlighted the potential for EKTERLY to become the first and only oral on-demand therapy for this younger pediatric population, with a New Drug Application (NDA) filing anticipated in the third quarter of 2026.
Show more
1. Acquisition by Chiesi Group. The most significant factor driving the stock increase was the announcement on April 29, 2026, that Chiesi Group would acquire KalVista Pharmaceuticals for $27.00 per share in cash. This represented an equity consideration of approximately $1.9 billion and a 36% premium to KalVista's 30-day volume-weighted average share price as of April 28, 2026, causing the stock to surge by approximately 38-39%.
2. Positive Interim Phase 3 Results for Pediatric HAE Treatment. KalVista announced positive interim data on March 30, 2026, from its KONFIDENT-KID Phase 3 trial evaluating EKTERLY (sebetralstat) for the on-demand treatment of hereditary angioedema (HAE) attacks in children aged 2-11 years. This development highlighted the potential for EKTERLY to become the first and only oral on-demand therapy for this younger pediatric population, with a New Drug Application (NDA) filing anticipated in the third quarter of 2026.
Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The 71.2% change in KALV stock from 1/31/2026 to 5/16/2026 was primarily driven by a 270.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 15.61 | 26.73 | 71.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 15 | 56 | 270.3% |
| P/S Multiple | 55.6 | 26.1 | -53.2% |
| Shares Outstanding (Mil) | 54 | 55 | -1.3% |
| Cumulative Contribution | 71.2% |
Market Drivers
1/31/2026 to 5/16/2026| Return | Correlation | |
|---|---|---|
| KALV | 71.2% | |
| Market (SPY) | 7.1% | 13.9% |
| Sector (XLV) | -5.8% | 7.4% |
Fundamental Drivers
The 145.0% change in KALV stock from 10/31/2025 to 5/16/2026 was primarily driven by a 3825.7% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 10312025 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.91 | 26.73 | 145.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 56 | 3825.7% |
| P/S Multiple | 409.3 | 26.1 | -93.6% |
| Shares Outstanding (Mil) | 53 | 55 | -2.0% |
| Cumulative Contribution | 145.0% |
Market Drivers
10/31/2025 to 5/16/2026| Return | Correlation | |
|---|---|---|
| KALV | 145.0% | |
| Market (SPY) | 9.0% | 14.9% |
| Sector (XLV) | 1.4% | 14.1% |
Fundamental Drivers
The 94.1% change in KALV stock from 4/30/2025 to 5/16/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302025 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 13.77 | 26.73 | 94.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 56 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 26.1 | |
| Shares Outstanding (Mil) | 53 | 55 | -3.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2025 to 5/16/2026| Return | Correlation | |
|---|---|---|
| KALV | 94.1% | |
| Market (SPY) | 34.8% | 12.4% |
| Sector (XLV) | 5.1% | 16.5% |
Fundamental Drivers
The 213.4% change in KALV stock from 4/30/2023 to 5/16/2026 was primarily driven by a 9.2233720368547763E17% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302023 | 5162026 | Change |
|---|---|---|---|
| Stock Price ($) | 8.53 | 26.73 | 213.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 56 | 9.2233720368547763E17% |
| P/S Multiple | ∞ | 26.1 | |
| Shares Outstanding (Mil) | 28 | 55 | -48.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2023 to 5/16/2026| Return | Correlation | |
|---|---|---|
| KALV | 213.4% | |
| Market (SPY) | 84.7% | 18.9% |
| Sector (XLV) | 14.2% | 20.6% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| KALV Return | -30% | -49% | 81% | -31% | 91% | 66% | 41% |
| Peers Return | 12% | -0% | -5% | -19% | 77% | 4% | 58% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 100% |
Monthly Win Rates [3] | |||||||
| KALV Win Rate | 33% | 50% | 58% | 33% | 58% | 80% | |
| Peers Win Rate | 53% | 57% | 43% | 42% | 55% | 44% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 60% | |
Max Drawdowns [4] | |||||||
| KALV Max Drawdown | -71% | -75% | -33% | -50% | -33% | -16% | |
| Peers Max Drawdown | -35% | -39% | -35% | -43% | -38% | -20% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: BCRX, IONS, BMRN, REGN, ARWR. See KALV Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/15/2026 (YTD)
How Low Can It Go
| Event | KALV | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.2% | -9.5% |
| % Gain to Breakeven | 25.3% | 10.5% |
| Time to Breakeven | 20 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.7% | -6.7% |
| % Gain to Breakeven | 29.4% | 7.1% |
| Time to Breakeven | 12 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.8% | -24.5% |
| % Gain to Breakeven | 231.2% | 32.4% |
| Time to Breakeven | 467 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.1% | -33.7% |
| % Gain to Breakeven | 150.7% | 50.9% |
| Time to Breakeven | 210 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -28.4% | -19.2% |
| % Gain to Breakeven | 39.7% | 23.8% |
| Time to Breakeven | 44 days | 105 days |
In The Past
KalVista Pharmaceuticals's stock fell -6.3% during the 2025 US Tariff Shock. Such a loss loss requires a 6.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | KALV | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -20.2% | -9.5% |
| % Gain to Breakeven | 25.3% | 10.5% |
| Time to Breakeven | 20 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -22.7% | -6.7% |
| % Gain to Breakeven | 29.4% | 7.1% |
| Time to Breakeven | 12 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -69.8% | -24.5% |
| % Gain to Breakeven | 231.2% | 32.4% |
| Time to Breakeven | 467 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -60.1% | -33.7% |
| % Gain to Breakeven | 150.7% | 50.9% |
| Time to Breakeven | 210 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -28.4% | -19.2% |
| % Gain to Breakeven | 39.7% | 23.8% |
| Time to Breakeven | 44 days | 105 days |
In The Past
KalVista Pharmaceuticals's stock fell -6.3% during the 2025 US Tariff Shock. Such a loss loss requires a 6.8% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About KalVista Pharmaceuticals (KALV)
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; KVD900, which has completed Phase II clinical trial for an oral on-demand therapy for acute HAE attacks; and KVD824, an oral product candidate for the treatment of HAE. The company is headquartered in Cambridge, Massachusetts.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe KalVista Pharmaceuticals (KALV):
- Like an early-stage Vertex Pharmaceuticals, but specializing in developing drugs for hereditary angioedema (HAE) and diabetic macular edema (DME).
- Imagine a company like Biogen, but much earlier in its journey, focused intently on developing new oral drugs for specific conditions like hereditary angioedema (HAE) and diabetic macular edema (DME).
AI Analysis | Feedback
```html- KVD001: A plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of diabetic macular edema (DME).
- KVD900: An oral on-demand therapy for acute hereditary angioedema (HAE) attacks, which has completed Phase II clinical trials.
- KVD824: An oral product candidate currently in development for the treatment of hereditary angioedema (HAE).
AI Analysis | Feedback
KalVista Pharmaceuticals (KALV) is a clinical-stage pharmaceutical company. As described in the background, its product candidates (KVD001, KVD900, KVD824) are still in clinical trials (e.g., Phase II). Therefore, KalVista Pharmaceuticals does not currently have commercialized products for sale, and as a result, does not have major customers in the traditional sense of companies or individuals purchasing its products.
AI Analysis | Feedback
- Lonza Group AG (LONN)
- CordenPharma
- Halo Pharmaceutical
AI Analysis | Feedback
Benjamin L. Palleiko Chief Executive Officer and Director
Mr. Palleiko was appointed CEO in March 2024, having joined KalVista in August 2016 as Chief Financial Officer. He was later promoted to Chief Business Officer in 2019 and President in 2023. With over 25 years of industry experience, Mr. Palleiko spent a decade as an investment banker at firms including Robertson Stephens. His prior executive roles include SVP & CFO of Ore Pharmaceutical Holdings (ORXE) and Penwest Pharmaceuticals Co. (PPCO). He also founded Cielo Therapeutics, Inc. in 2012, serving as President, Secretary, Treasurer & Director until 2016. Before his business career, he served as a Naval Aviator in the U.S. Navy.
Brian Piekos Chief Financial Officer
Mr. Piekos joined KalVista as Chief Financial Officer in September 2024. He brings over 25 years of financial and strategic planning experience in the biopharmaceutical industry. Prior to KalVista, he was CFO at Elicio Therapeutics, where he was responsible for launching the company as a public entity. He also served as CFO for Gemini Therapeutics and as Executive Vice President, CFO and Treasurer at AMAG Pharmaceuticals. Mr. Piekos held leadership roles in corporate finance, tax, and treasury at Cubist Pharmaceuticals and started his career as a healthcare investment banker at Needham & Company and Leerink Partners.
Bilal Arif Chief Operating Officer
Mr. Arif is the Chief Operating Officer at KalVista Pharmaceuticals.
Linea Aspesi Chief People Officer
Ms. Aspesi is the Chief People Officer at KalVista Pharmaceuticals.
Paul K. Audhya, MD, MBA Chief Medical Officer
Dr. Audhya is the Chief Medical Officer at KalVista Pharmaceuticals.
AI Analysis | Feedback
Key Risks to KalVista Pharmaceuticals (KALV)
For KalVista Pharmaceuticals (KALV), a clinical-stage pharmaceutical company transitioning to commercialization, the key risks are primarily centered on intense market competition, significant cash burn, and ongoing regulatory and commercialization hurdles.
- Intense Competition and Evolving HAE Treatment Landscape: KalVista's lead product, sebetralstat (Ekterly), an oral on-demand therapy for hereditary angioedema (HAE), faces substantial threats from a rapidly evolving competitive environment. While Ekterly has achieved a first-mover advantage in some markets, it faces looming competition from other upcoming oral HAE therapies, such as those from Pharvaris. More significantly, Intellia Therapeutics' CRISPR program, lonvoguran ziclumeran (Lonvo-z), is a potential "functional cure" in Phase 3 development with promising data, which could disrupt the entire HAE treatment market by 2027. Additionally, the increasing effectiveness of prophylactic HAE treatments is leading to a shrinking market for on-demand therapies, thereby challenging Ekterly's long-term growth trajectory and market sustainability.
- Significant Cash Burn and Future Financing Needs: KalVista Pharmaceuticals is currently experiencing a substantial rate of cash expenditure. For the first nine months of fiscal year 2025, the company reported a cash burn of $127.0 million, and it is estimated that approximately $200 million in sales will be required to reach breakeven. While KalVista held $309.2 million in cash and marketable securities as of September 30, 2025, and has utilized synthetic royalty agreements to secure additional funding, continued high operational costs necessitate considerable commercial success of its products. Analysts project that the company will need to either effectively reduce its cash burn or seek further capital raises if it is to achieve cash flow breakeven within the anticipated timeframe.
- Regulatory and Commercialization Hurdles: Despite receiving approvals for sebetralstat in several countries, KalVista has encountered delays in securing full regulatory approval in critical markets, such as the U.S. The FDA did not meet the PDUFA goal date for sebetralstat's New Drug Application (NDA) in June 2025, citing heavy workload and limited resources. Beyond regulatory clearance, successful commercialization involves overcoming significant challenges, including achieving broad market adoption, securing favorable reimbursement policies, and effectively executing sales and marketing strategies in a highly competitive therapeutic area.
AI Analysis | Feedback
The emergence of other highly effective oral therapies for hereditary angioedema (HAE) from competing pharmaceutical companies, such as Pharvaris's oral bradykinin B2 receptor antagonist (PHA-121) which is in clinical development for both on-demand and prophylactic HAE, represents a clear emerging threat. These competing oral therapies could potentially capture significant market share or establish themselves as preferred treatments, directly impacting the commercial prospects of KalVista's oral HAE product candidates (KVD900 and KVD824).AI Analysis | Feedback
KalVista Pharmaceuticals (symbol: KALV) operates in two key addressable markets for its main products: Diabetic Macular Edema (DME) and Hereditary Angioedema (HAE). For its product KVD001, targeting Diabetic Macular Edema, the global market size for DME treatment was estimated at approximately $5 billion in 2024 and is projected to reach $8 billion by 2030. North America held the largest share of the diabetic macular edema market in 2025. For its products KVD900 and KVD824, which are focused on Hereditary Angioedema, the global hereditary angioedema treatment market was valued at USD 7.64 billion in 2026 and is projected to grow to USD 27.06 billion by 2034. North America significantly dominates this market, accounting for 90.66% of the share in 2025. The United States hereditary angioedema therapeutics market is expected to reach a projected revenue of US$ 2,047.2 million by 2030.AI Analysis | Feedback
KalVista Pharmaceuticals (NASDAQ: KALV) is poised for significant revenue growth over the next 2-3 years, primarily driven by the expanding commercialization and market penetration of its oral on-demand hereditary angioedema (HAE) therapy, EKTERLY (sebetralstat). The company's strategic focus on this product, coupled with its global expansion plans and pipeline advancements, are expected to be key catalysts.
The primary drivers of future revenue growth for KalVista Pharmaceuticals include:
- Continued Ramp-up and Adoption of EKTERLY in Existing Markets: Following its successful U.S. commercial launch on July 7, 2025, and strong early adoption in Germany, EKTERLY has demonstrated promising initial market performance. The company reported approximately $49 million in global net product revenue for the full year 2025, with prescription refills surpassing initial prescriptions as the primary revenue driver in the fourth quarter of 2025, indicating growing real-world use and patient retention. Analysts project a substantial increase in EKTERLY sales, with estimates for 2026 reaching $170.8 million, up from previous forecasts. This strong momentum in key markets is expected to continue driving revenue growth in the near term.
- Expansion of EKTERLY into New International Markets: KalVista Pharmaceuticals is actively pursuing global expansion for EKTERLY. The company secured regulatory approvals for EKTERLY in seven major global markets, including the United States, United Kingdom, European Union, Switzerland, Australia, Singapore, and Japan, in 2025. Upcoming commercial launches are anticipated in the UK in the first half of 2026 and in Japan in early 2026. Furthermore, KalVista has established strategic licensing agreements with partners such as Kaken Pharmaceutical for Japan, Pendopharm for Canada, and Multicare Pharmaceuticals, LLC for Latin America (Brazil, Argentina, Colombia, and Mexico), which are expected to broaden the product's reach and contribute to international revenue growth.
- Approval and Launch of EKTERLY for Pediatric HAE Patients: KalVista has successfully completed enrollment in its Phase 3 KONFIDENT-KID trial for pediatric HAE patients aged 2 to 11 years, a full year ahead of schedule. The company expects to file a new drug application (NDA) for this expanded patient population in the third quarter of 2026, with a U.S. launch anticipated in 2027. This pediatric indication will significantly expand the eligible patient population for EKTERLY, offering a new avenue for substantial revenue growth.
AI Analysis | Feedback
Share Issuance
- In February 2024, KalVista Pharmaceuticals completed a public offering that generated $150.1 million in net proceeds.
- In September 2025, the company priced an upsized offering of $125.0 million in 3.250% Convertible Senior Notes due 2031, with estimated net proceeds of approximately $120.8 million.
- In November 2024, KalVista completed an underwritten public offering of 5,500,000 shares for $55 million in gross proceeds.
Inbound Investments
- In November 2024, DRI Healthcare Trust acquired a royalty interest in sebetralstat from KalVista for an aggregate purchase price of up to $179 million, including a $100 million upfront payment.
- Concurrently with the royalty deal in November 2024, DRI Healthcare Trust also made a $5 million equity investment in KalVista's common stock through a private placement.
Outbound Investments
- KalVista Pharmaceuticals has not made any investments or acquisitions.
Capital Expenditures
- KalVista Pharmaceuticals' capital expenditures were approximately $0.44 million in 2024 and $0.93 million in 2025.
- The company's capital expenditures were approximately -$0.4 million by 2025.
Latest Trefis Analyses
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to KALV.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 04302026 | GEHC | GE HealthCare Technologies | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | IQV | IQVIA | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | UHS | Universal Health Services | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ABT | Abbott Laboratories | Dip Buy | DB | P/E OPMDip Buy with Low PE and High MarginBuying dips for companies with tame PE and meaningfully high operating margin | 0.0% | 0.0% | 0.0% |
| 04302026 | ZBIO | Zenas BioPharma | Insider | Insider Buys 45DStrong Insider BuyingCompanies with multiple insider buys in the last 45 days | 0.0% | 0.0% | 0.0% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 63.02 |
| Mkt Cap | 10.4 |
| Rev LTM | 972 |
| Op Inc LTM | -200 |
| FCF LTM | 310 |
| FCF 3Y Avg | 60 |
| CFO LTM | 313 |
| CFO 3Y Avg | 62 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 14.1% |
| Rev Chg 3Y Avg | 24.9% |
| Rev Chg Q | 7.5% |
| QoQ Delta Rev Chg LTM | 2.6% |
| Op Inc Chg LTM | -26.2% |
| Op Inc Chg 3Y Avg | -16.9% |
| Op Mgn LTM | -34.5% |
| Op Mgn 3Y Avg | -20.6% |
| QoQ Delta Op Mgn LTM | -1.5% |
| CFO/Rev LTM | 27.0% |
| CFO/Rev 3Y Avg | 0.6% |
| FCF/Rev LTM | 23.4% |
| FCF/Rev 3Y Avg | 0.2% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 10.4 |
| P/S | 8.2 |
| P/Op Inc | -6.9 |
| P/EBIT | -7.3 |
| P/E | -6.3 |
| P/CFO | 7.0 |
| Total Yield | -2.7% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | 0.6% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -2.8% |
| 3M Rtn | 6.1% |
| 6M Rtn | 15.6% |
| 12M Rtn | 69.7% |
| 3Y Rtn | 55.5% |
| 1M Excs Rtn | -8.0% |
| 3M Excs Rtn | -2.3% |
| 6M Excs Rtn | 6.0% |
| 12M Excs Rtn | 49.6% |
| 3Y Excs Rtn | -32.1% |
FDA Approved Drugs Data
Expand for More| Post-Approval Fwd Returns | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| FDA App # | Brand Name | Generic Name | Dosage Form | FDA Approval | 3M Rtn | 6M Rtn | 1Y Rtn | 2Y Rtn | Total Rtn |
| NDA219301 | EKTERLY | sebetralstat | tablet | 7032025 | -0.3% | 37.1% | 126.9% | 126.9% | 126.9% |
Price Behavior
Price Behavior
| Market Price | $26.73 | |
| Market Cap ($ Bil) | 1.4 | |
| First Trading Date | 04/09/2015 | |
| Distance from 52W High | -0.3% | |
| 50 Days | 200 Days | |
| DMA Price | $20.75 | $15.66 |
| DMA Trend | up | up |
| Distance from DMA | 28.8% | 70.7% |
| 3M | 1YR | |
| Volatility | 94.3% | 74.4% |
| Downside Capture | -160.69 | 73.91 |
| Upside Capture | 106.48 | 150.58 |
| Correlation (SPY) | 9.7% | 12.4% |
KALV Betas & Captures as of 4/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.81 | 0.77 | 1.01 | 1.00 | 0.77 | 0.81 |
| Up Beta | 1.89 | 1.79 | 1.78 | 1.14 | 0.69 | 0.61 |
| Down Beta | 9.82 | -1.05 | 0.43 | -0.17 | 0.11 | 0.86 |
| Up Capture | 109% | 136% | 142% | 254% | 128% | 97% |
| Bmk +ve Days | 15 | 22 | 31 | 66 | 141 | 428 |
| Stock +ve Days | 13 | 22 | 33 | 67 | 121 | 368 |
| Down Capture | 771% | 58% | 47% | 79% | 104% | 96% |
| Bmk -ve Days | 4 | 18 | 30 | 56 | 108 | 321 |
| Stock -ve Days | 9 | 21 | 30 | 56 | 128 | 375 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KALV | |
|---|---|---|---|---|
| KALV | 84.8% | 68.9% | 1.15 | - |
| Sector ETF (XLV) | 14.8% | 14.9% | 0.71 | 17.3% |
| Equity (SPY) | 27.4% | 12.1% | 1.71 | 16.0% |
| Gold (GLD) | 42.5% | 26.8% | 1.30 | 6.4% |
| Commodities (DBC) | 45.4% | 18.5% | 1.88 | 5.2% |
| Real Estate (VNQ) | 11.5% | 13.5% | 0.56 | 4.0% |
| Bitcoin (BTCUSD) | -23.7% | 41.8% | -0.54 | 6.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KALV | |
|---|---|---|---|---|
| KALV | -3.2% | 65.6% | 0.26 | - |
| Sector ETF (XLV) | 4.8% | 14.7% | 0.15 | 18.3% |
| Equity (SPY) | 13.6% | 17.1% | 0.63 | 21.5% |
| Gold (GLD) | 19.4% | 17.9% | 0.88 | 2.2% |
| Commodities (DBC) | 10.9% | 19.4% | 0.45 | 0.1% |
| Real Estate (VNQ) | 2.9% | 18.8% | 0.06 | 19.7% |
| Bitcoin (BTCUSD) | 7.2% | 55.9% | 0.34 | 13.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with KALV | |
|---|---|---|---|---|
| KALV | 7.2% | 81.1% | 0.43 | - |
| Sector ETF (XLV) | 9.6% | 16.5% | 0.47 | 18.1% |
| Equity (SPY) | 15.5% | 17.9% | 0.74 | 19.4% |
| Gold (GLD) | 13.0% | 16.0% | 0.67 | 2.7% |
| Commodities (DBC) | 8.3% | 17.9% | 0.38 | 6.9% |
| Real Estate (VNQ) | 5.0% | 20.7% | 0.21 | 16.5% |
| Bitcoin (BTCUSD) | 67.4% | 66.9% | 1.06 | 6.4% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/25/2026 | 4.1% | 22.3% | 15.9% |
| 11/10/2025 | 5.3% | 36.5% | 55.2% |
| 7/10/2025 | -3.0% | -1.3% | -20.8% |
| 3/12/2025 | -1.6% | -2.8% | -15.3% |
| 12/5/2024 | 8.3% | -3.4% | -3.3% |
| 7/11/2024 | 4.3% | 13.6% | 3.2% |
| 2/16/2024 | -7.1% | -7.9% | -20.3% |
| 12/7/2023 | -9.0% | 17.1% | 42.4% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 10 | 11 | 8 |
| # Negative | 9 | 8 | 11 |
| Median Positive | 4.7% | 9.7% | 19.9% |
| Median Negative | -5.3% | -4.6% | -13.4% |
| Max Positive | 8.3% | 36.5% | 55.2% |
| Max Negative | -9.0% | -8.4% | -20.8% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/14/2026 | 10-Q |
| 12/31/2025 | 03/25/2026 | 10-KT |
| 09/30/2025 | 11/10/2025 | 10-Q |
| 07/31/2025 | 09/11/2025 | 10-Q |
| 04/30/2025 | 07/10/2025 | 10-K |
| 01/31/2025 | 03/12/2025 | 10-Q |
| 10/31/2024 | 12/05/2024 | 10-Q |
| 07/31/2024 | 09/05/2024 | 10-Q |
| 04/30/2024 | 07/11/2024 | 10-K |
| 01/31/2024 | 03/11/2024 | 10-Q |
| 10/31/2023 | 12/07/2023 | 10-Q |
| 07/31/2023 | 09/07/2023 | 10-Q |
| 04/30/2023 | 07/10/2023 | 10-K |
| 01/31/2023 | 03/09/2023 | 10-Q |
| 10/31/2022 | 12/08/2022 | 10-Q |
| 07/31/2022 | 09/08/2022 | 10-Q |
Recent Forward Guidance [BETA]
Latest: Q4 2025 Earnings Reported 3/25/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| Q3 2026 US New Drug Application Filing | |||||||
| 2027 US Launch | |||||||
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Palleiko, Benjamin L | CHIEF EXECUTIVE OFFICER | Direct | Sell | 5132026 | 26.71 | 3,322 | 88,731 | 12,456,876 | Form |
| 2 | Audhya, Paul K | CHIEF MEDICAL OFFICER | Direct | Sell | 4202026 | 20.22 | 2,686 | 54,301 | 2,881,773 | Form |
| 3 | Sweeny, Nicole | Chief Commercial Officer | Direct | Sell | 4202026 | 20.22 | 1,862 | 37,643 | 1,038,936 | Form |
| 4 | Piekos, Brian | Chief Financial Officer | Direct | Sell | 4202026 | 20.22 | 1,862 | 37,643 | 366,926 | Form |
| 5 | Palleiko, Benjamin L | CHIEF EXECUTIVE OFFICER | Direct | Sell | 4202026 | 20.22 | 9,550 | 193,066 | 9,351,595 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.